GlaxoSmithKline and Vir aim to take on Covid-19 with antibodies and CRISPR
SANG TAN/AP
The drug giant GlaxoSmithKline is collaborating with Vir Biotechnology on experimental treatments and potentially, vaccines against the novel coronavirus.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario